Sep 11 - Apple (NASDAQ:AAPL) was cut to Reduce from Neutral at Phillip Securities, with the brokerage citing stretched ...

Phase 1 proof-of-concept study will evaluate the safety, tolerability, and pharmacokinetics of GlyphAgo and is designed to demonstrate therapeutic levels of agomelatine at lower d ...